Sanofi: Annual EPS up 4% at CER
(CercleFinance.com) - Sanofi reports business EPS of E7.
12 for 2024, down 1.8% on a reported basis but up 4.1% at CER (constant exchange rates), thus exceeding its forecasts, with Sanofi proposing an annual dividend of E3.92 per share.
At E41.1bn, the healthcare giant's sales rose by 11.3% at CER, with its Dupixent exceeding E13bn and its Beyfortus having achieved blockbuster status (E1.7bn) in its first full year on the market.
By 2025, Sanofi expects sales growth in the mid-to-high single-digits at CER, and confirms that it expects EPS from growing businesses in the low double-digits at CER (excluding share buybacks).
The group also plans to carry out a share buyback program worth E5bn this year. The shares will be purchased preferably through block trades and on the open market, with the aim of cancelling them.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
12 for 2024, down 1.8% on a reported basis but up 4.1% at CER (constant exchange rates), thus exceeding its forecasts, with Sanofi proposing an annual dividend of E3.92 per share.
At E41.1bn, the healthcare giant's sales rose by 11.3% at CER, with its Dupixent exceeding E13bn and its Beyfortus having achieved blockbuster status (E1.7bn) in its first full year on the market.
By 2025, Sanofi expects sales growth in the mid-to-high single-digits at CER, and confirms that it expects EPS from growing businesses in the low double-digits at CER (excluding share buybacks).
The group also plans to carry out a share buyback program worth E5bn this year. The shares will be purchased preferably through block trades and on the open market, with the aim of cancelling them.
Copyright (c) 2025 CercleFinance.com. All rights reserved.